1. Patients who are participating in other drug clinical trials, 2. Pregnant or lactating women, 3. ALT / AST> 5 ULN, neutrophils <0.5, platelets less than 50, 4. Expected life<1 week, 5. Definite diagnosis of asthma-related diseases, 6. Long-term oral anti-rejection or immunomodulatory drugs, 7. Hypersensitivity to tocilizumab or any excipients, 8. Patients with active pulmonary tuberculosis, with definite bacterial and fungal infections.

1. Patients who are participating in other drug clinical trials, 2. Pregnant or lactating women, 3. ALT / AST> 5 ULN, neutrophils <0.5, platelets less than 50, 4. Expected life<1 week, 5. Definite diagnosis of asthma-related diseases, 6. Long-term oral anti-rejection or immunomodulatory drugs, 7. Hypersensitivity to tocilizumab or any excipients, 8. Patients with active pulmonary tuberculosis, with definite bacterial and fungal infections.